663 results about "Umbilical cord" patented technology

The invention provides an exosome, a mesenchymal stem cell and application of the exosome and the mesenchymal stem cell in treatment of type 2 diabetes mellitus, and belongs to the technical field of biological medicine. The exosome secreted by the umbilical cord mesenchymal stem cells of the composite pretreatment group is used for treating the type 2 diabetes mellitus, and the obvious advantages are shown. Compared with a model control group, the exosome has the advantages that the glucose tolerance of diabetic rats treated by the exosome is obviously improved, the blood glucose value is reduced by about 47.5% within 120 minutes, the area under a blood glucose curve (AUC) is reduced by about 50.5%, the serum insulin is increased by about 147.7%, insulin secretion is effectively promoted, the glycosylated hemoglobin level is obviously reduced, and the long-term blood glucose control effect is good. By integrating various indexes, the exosome obtained by the composite pretreatment scheme provided by the invention has a remarkable effect of improving the illness state of rats with type 2 diabetes mellitus, provides a new effective strategy for treatment of type 2 diabetes mellitus, and shows a good application prospect.

The invention relates to the technical field of biological medicines, in particular to an umbilical cord mesenchymal stem cell exosome and application of the umbilical cord mesenchymal stem cell exosome in preparation of a medicine for treating male infertility caused by hidden testis. The prepared high-concentration umbilical cord mesenchymal stem cell exosome suspension preparation is directly used for treating cultured spermatogonial cells and spermatoblasts in vitro, is injected into the testis of a mouse, and is used for improving the seminiferous tubule and spermatogenic microenvironment of testis tissue and promoting division and proliferation of the spermatogonial cells and the spermatoblasts. The method can effectively reverse oligospermia and azoospermia caused by the hidden testis, and compared with a model without intervention of treatment means, the method can effectively promote increase and even regeneration of sperms in the testis.

The invention provides application of an enhanced and optimized mesenchymal stem cell exosome in knee osteoarthritis and muscle cartilage injury, and belongs to the technical field of biological medicine. The treatment activity of the umbilical cord mesenchymal stem cell exosome is remarkably improved by combining a composite pretreatment technology with a 3D culture system. Through the synergistic effect of the total flavonoids of rhizoma drynariae and tanshinone IIA, the pathological process of knee osteoarthritis can be regulated and controlled in multiple dimensions, including inflammatory reaction inhibition, cartilage repair promotion and joint function improvement, and the functional limitation of single-component pretreatment is broken through. The invention provides a safe and efficient novel treatment technical strategy for relieving knee osteoarthritis and muscle cartilage injury, and has a wide clinical application prospect.

The invention relates to a medicine, a medicine composition and application of the medicine and the medicine composition in treatment of liver fibrosis. The medicine and the medicine composition comprise an umbilical cord mesenchymal stem cell membrane; the umbilical cord mesenchymal stem cell membrane is prepared by the following steps: coating the surface of a temperature-sensitive culture dish with a matrix; adding the cell suspension of the umbilical cord mesenchymal stem cells into a temperature-sensitive culture dish for culturing; the temperature is reduced, the umbilical cord mesenchymal stem cells and the extracellular matrix secreted by the umbilical cord mesenchymal stem cells are separated in a lamellar mode, and the umbilical cord mesenchymal stem cell membrane is obtained. The medicine and the medicine composition provided by the invention can effectively relieve liver fibrosis.

The invention discloses a cord blood-derived regulatory T cell amplification culture medium and a use method thereof, and relates to the field of animal cell culture and immune cell therapy, the culture medium is a serum-free culture medium, the culture medium is composed of a basic culture medium, a serum substitute combination, a combination of four cell factors, an immunosuppressor, an apparent stabilizer and an antioxidant, and all the components play a role synergistically; according to the use method, cell amplification is realized through a collaborative process of staged environmental regulation and targeted activation. According to the method, the problems of exogenous pollution and batch difference caused by dependence of a serum-containing system on cord blood-derived regulatory T cell amplification in the prior art are solved, the defect that a serum-free scheme is difficult to consider the amplification efficiency and the function stability at the same time is overcome, the cell amplification quality and the clinical application safety are guaranteed, and the method is suitable for large-scale clinical transformation requirements.

The invention discloses a stem cell exosome based on targeted fusion polypeptide modification, a preparation method and application of the stem cell exosome in treating male erectile dysfunction. According to the exosome, a specific targeting fusion polypeptide (sequence: EPLQLKM-GGGS-DPPV) is anchored on the surface through a chemical coupling technology, so that the targeting property of the exosome on cavernosum smooth muscle cells is enhanced; meanwhile, an anti-TrkA monoclonal antibody (TrkA-2E7-HL) is loaded through an electroporation method, and a fibrosis pathway mediated by a nerve growth factor (NGF) is inhibited. The exosome induces secretion of the umbilical cord mesenchymal stem cells by adopting an anti-oxidation culture medium, so that the anti-oxidation activity of the exosome is remarkably improved. Experiments show that in a diabetes ED rat model, the erectile function (ICP / MAP ratio) of the modified exosome is improved to 0.79 + / -0.05, the fibrosis area is reduced to 9.2 + / -1.6%, and the NO secretion level is improved by 3.5 times compared with that of a common exosome. Through triple mechanisms of polypeptide targeting, antibody synergy and oxidation resistance, effective reversion of the ED pathological process is realized, and the polypeptide has remarkable novelty and clinical transformation potential.

The invention discloses a therapeutic nano-vesicle preparation rich in mitochondrial functional protein, a preparation method of the therapeutic nano-vesicle preparation and application of the therapeutic nano-vesicle preparation in treatment of radioactive skin injury. The preparation method comprises the following steps: culturing, amplifying and cleaning umbilical cord mesenchymal stem cells, dispersing the umbilical cord mesenchymal stem cells in a suspension, mechanically extruding the umbilical cord mesenchymal stem cells into a crude solution through a multistage aperture polycarbonate membrane, and centrifuging, concentrating and purifying the crude solution to obtain the preparation. The preparation has the remarkable advantages that local administration can be realized, inflammation can be quickly inhibited, oxidative stress is reduced, and a repair pathway is activated, so that the preparation is suitable for treating acute radioactive skin injury; the preparation method is easy to standardize and scale, high in stability and convenient for emergency storage and delivery, and avoids the defects of cell therapy; a plurality of targets such as immune inflammation, oxidative stress and the like can be synergistically regulated, the biological effect of hUMSCs is simulated and partially replaced, and the limitation caused by the cell survival rate and the microenvironment dependency is avoided; the key function of hUMSCs is covered in function, and the clinical feasibility, safety and emergency suitability of the application level are higher.

The invention relates to the technical field of stem cell injections, in particular to a human umbilical cord mesenchymal stem cell injection and a preparation method thereof. The cell cryoprotectant comprises the following components: a cell cryoprotectant and P6-generation human umbilical cord mesenchymal stem cells. By selecting P6-generation human umbilical cord mesenchymal stem cells, the capacity of secreting hepatocyte growth factors (HGF) can be improved; the cell cryoprotectant contains 6-9wt% of dimethyl sulfoxide and a certain amount of human serum albumin, can better protect cells and maintain the motility rate and biological functions of the cells, and is more beneficial to preparation of cryopreserved human umbilical cord mesenchymal stem cell injection. The P6-generation human umbilical cord mesenchymal stem cells are obtained by culturing a culture medium containing fetal calf serum, and the ability of the injection to repair liver injury can be improved.

The invention belongs to the technical field of biological medicines, and particularly relates to an umbilical cord mesenchymal stem cell preparation and application thereof in treating prostate diseases. According to the umbilical cord mesenchymal stem cell preparation, the umbilical cord mesenchymal stem cells of the third generation to the sixth generation and the neurofilament peptide serve as active components, pharmaceutically acceptable auxiliary materials are matched, the prostate index can be remarkably reduced, the concentration of PACP and SRD5A2 can be reduced, and the umbilical cord mesenchymal stem cell preparation has a remarkable curative effect on prostatic hyperplasia. And the umbilical cord mesenchymal stem cells of the third generation to the sixth generation and the neurofilament peptide supplement each other and have a synergistic effect, so that a remarkable progress is generated.

The invention discloses a method for increasing the yield of mesenchymal stem cell exosomes. A main culture medium used in the method is a human umbilical cord mesenchymal stem cell serum-free culture medium, and different natural compounds are respectively added in three main stages of mesenchymal stem cell growth, namely a recovery stage, an amplification stage and a stable stage, so that the characteristics of the mesenchymal stem cells in the stages are pertinently improved; the survival rate of the mesenchymal stem cells is protected in stages, the amplification efficiency of the mesenchymal stem cells is improved, the stability of the mesenchymal stem cells is maintained, and the exosome secretion amount of the mesenchymal stem cells can be remarkably increased through combined use of the three natural compounds. According to the invention, the secretion amount of the exosome of the mesenchymal stem cells can be obviously increased, and the problem of low yield of the mesenchymal stem cells at present is solved.

The invention discloses a method for culturing CIK (Cytokine-Induced Killer) cells and application thereof. The method comprises the following steps: recovering cord blood, mixing and centrifuging the recovered cord blood and a buffer solution, re-suspending and precipitating, centrifuging again to obtain cord blood mononuclear cells, inoculating the cord blood mononuclear cells into an activation culture medium, and culturing to obtain the CIK cells, the buffer solution contains L-proline, human recombinant DNA enzyme and angelica polysaccharide. According to the method, the mononuclear cells can be separated from the umbilical cord blood preserved by liquid nitrogen, the utilization rate of the umbilical cord blood which can only be discarded due to insufficient cells is increased, the traditional lymphocyte separation process is optimized, the recovery rate of the mononuclear cells is increased, and the cost is reduced. The method provided by the invention can be used for culturing dozens to ten billions of CIK cells from a small amount of cryopreserved cord blood, and has huge advantages in the field of CIK cell culture and application.

The invention provides a small extracellular vesicle composite collagen hydrogel injection, and belongs to the technical field of osteoarthritis, and the small extracellular vesicle composite collagen hydrogel injection is prepared by the following steps: S1, mixing a sodium alginate solution with a type I collagen solution to obtain a mixed solution, adding a CaCl2 solution into the mixed solution to form gel, adding an FGF18 solution into the gel, and mixing to obtain FGF18 sodium alginate / collagen hydrogel; s2, transfecting a Lenti-IGF-1-EGF lentiviral vector to P3 generation human umbilical cord mesenchymal stem cells, culturing to obtain P5 generation IGF-1 overexpressed MSCs cells, namely P5 generation IGF-1-MSCs cells, co-culturing with the P5 generation IGF-1-MSCs cells by using curcumin, and separating and extracting a small extracellular vesicle solution rich in curcumin; and S3, mixing the small extracellular vesicle solution rich in curcumin with the FGF18 sodium alginate / collagen hydrogel, so as to obtain the small extracellular vesicle composite collagen hydrogel injection. The invention provides a small extracellular vesicle composite collagen hydrogel injection, which achieves the purposes of relieving inflammatory injury of osteoarthritis and enhancing the treatment effect of osteoarthritis.

The invention discloses a ready-to-use activated human umbilical cord mesenchymal stem cell as well as a preparation method and application thereof. The preparation method comprises the following steps: carrying out passage on P0-generation cells for three times to obtain P3-generation cells; cryopreserving P3 generation cells, and establishing a cell seed bank; resuscitating the cells in the seed bank for three times of passage to obtain P6-generation cells; and carrying out activation culture on the P6-generation cells, and resuspending the activated P6-generation cells in a cell protective agent to obtain the human umbilical cord mesenchymal stem cell original suspension. The invention also discloses an umbilical cord mesenchymal stem cell cryopreservation preparation. The cryopreservation preparation is obtained by mixing the human umbilical cord mesenchymal stem cell original suspension with a cryopreservation protective agent, sub-packaging and cryopreserving. Experiments prove that the human umbilical cord mesenchymal stem cell cryopreserved preparation prepared by the invention can be stored for a long time, is convenient to store, transport and use clinically, can complete effectiveness and safety index detection within the shelf life, and has the same activity as a fresh preparation.

The invention relates to the technical field of biomedicine, in particular to a method for efficiently separating and preparing exosomes, which comprises the following steps: S10, providing human umbilical cord mesenchymal stem cells; s20, culturing the human umbilical cord mesenchymal stem cells by using an exosome induction culture medium; the exosome induction culture medium contains a first inflammatory factor; a second inflammatory factor is added in the culture process; the first inflammatory factor comprises at least one selected from the following groups: IL-6 and TNF-alpha; the second inflammatory factor comprises CCL2; and S30, collecting the supernatant of the culture medium in the step S20, and centrifugally collecting to obtain the exosome. The method can improve the yield of the exosomes, has the advantage of simple operation, is suitable for extracting a large amount of exosomes, and has a good clinical application prospect.

The invention discloses application of a stem cell exosome in treating depression-like behaviors caused by high-altitude hypoxia, and belongs to the technical field of biomedicine. The stem cell exosome is an exosome derived from human umbilical cord mesenchymal stem cells, and is used for drugs for preventing and / or treating depression-like behaviors caused by high-altitude hypoxia. The exosome can effectively improve depression-like core behavior symptoms caused by high-altitude hypoxia by regulating a brain-intestinal axis; the method starts from remodeling intestinal flora so as to influence the intracerebral metabolite spectrum, and finally plays a role in neuroprotection by regulating and controlling a 5-HT6 / cAMP-PKA key signal channel. In addition, the combination of the hUC-MSC-exo and probiotics shows synergistic interaction potential, and a potential treatment strategy which is novel in mechanism, remarkable in effect and high in safety is provided for the field.

The invention relates to the technical field of cell drug preparation process optimization, in particular to an umbilical cord stem cell drug preparation parameter optimization method utilizing machine learning, which comprises the following steps: preprocessing to generate a control input time sequence and an observation output time sequence, and forming a process instruction library; constructing an intervening state space model based on the two types of time sequences, and assimilating the intervening state space model; defining multiple targets and constraints, compiling a process, simulating on the model, determining a feasible region by combining statistical calibration and formalized verification, and generating a feasibility judgment function; and carrying out microparameterization on the process in the feasible region and optimizing under constraints, carrying out rolling solution according to a preset prediction window in the model prediction control framework, outputting an optimal process flow and a monitoring threshold value, and executing record backflow updating. According to the method, the replicability, the compliance and the cross-batch robustness of the process are enhanced.

The invention relates to the technical field of biological medicines, in particular to an umbilical cord source mesenchymal stem cell exosome preparation, a preparation method and application in preparation of osteoarthritis medicines. The preparation is prepared by the method. The method comprises the following steps: pretreating umbilical cord-derived mesenchymal stem cells by adopting a pretreating agent; removing the pretreatment agent, and carrying out gradient centrifugation treatment on the pretreated umbilical cord source mesenchymal stem cells to obtain exosome precipitate; and re-suspending the exosome precipitate in a buffer solution containing a protease inhibitor to obtain the umbilical cord source mesenchymal stem cell exosome preparation. The application refers to the application of the preparation in preparation of osteoarthritis drugs. The problems of low yield and functional heterogeneity of EXO obtained by a conventional culture method are solved.

The invention belongs to the technical field of biology, and particularly relates to polypeptide for promoting proliferation of mesenchymal stem cells and application of the polypeptide. The amino acid sequence of the polypeptide for promoting proliferation of the mesenchymal stem cells is shown as SEQ ID NO: 1. The active polypeptide for promoting proliferation of the umbilical cord mesenchymal stem cells is obtained by adopting a solid-phase synthesis method. Umbilical cord mesenchymal stem cells obtained by culturing the polypeptide have good adherence and multiplication capacities. In addition, the polypeptide can promote Nrf2 gene expression, so that proliferation of the umbilical cord mesenchymal stem cells is effectively promoted.

The invention discloses a natural product-induced artificial nano-vesicle derived from human umbilical cord mesenchymal stem cells and application of the natural product-induced artificial nano-vesicle in ischemic diseases. The preparation method of the nano vesicle derived from the human umbilical cord mesenchymal stem cells comprises the following steps: S1, inoculating the human umbilical cord mesenchymal stem cells to a 3D microcarrier; then adding traditional Chinese medicine active ingredients to activate the human umbilical cord mesenchymal stem cells, continuing to culture, cracking the microcarrier, and harvesting cells; s2, dispersing the human umbilical cord mesenchymal stem cells obtained in S1 to obtain a suspension, extruding the suspension through a polycarbonate film, and then discarding large particles by adopting a gradient centrifugation method to obtain the nano-vesicles. Compared with naturally secreted exosomes, the exosome has the advantages that the yield is increased, the treatment efficiency is improved, the production cost is reduced, and compared with stem cells, the problems of low transplantation rate and the like are avoided. The stem cells are pretreated based on the traditional Chinese medicine, the vesicles are extracted by utilizing an extrusion method, and the yield and the treatment efficiency of the nano vesicles are remarkably improved.

Disclosed herein are methods for isolation and expansion of umbilical cord-derived mesenchymal stem cells (UC-MSCs) having one or more cell surface markers, and compositions comprising such UC-MSCs. Also disclosed herein are further processing methods for use in connection with the UC-MSCs to isolate extracellular vesicles (EVs) therefrom. Also disclosed herein are lyophilized EVs isolated from the UC-MSCs, and adapted for use as a therapeutic product.

The present invention relates to an incubation system for liquid-based incubation of prematurely born infants, comprising: —an inner chamber forming an amniotic basin comprising amniotic fluid, said basin being configured for holding said infant and being made from a flexible material configured for expanding said inner chamber volume in correspondence with the growth of said infant; —an outer chamber enclosing said inner chamber and comprising a temperature regulation fluid, —a fetal connection port, arranged for connecting with the umbilical cord of said infant, said umbilical cord providing a port in said inner chamber to said infant for providing dialyzation and nutrition compounds to said infant via said umbilical cord; —a fetal control unit, connected to said fetal connection port for control of said dialyzation and control of said provided nutrition by monitoring and controlling one or more of a pressure, flow and temperature thereof; an amniotic fluid circulation unit, arranged for connecting with an inlet / outlet port of said inner chamber and comprising a pump for circulating said amniotic fluid from said inner chamber and through a purification system located outside said inner chamber; and —a temperature regulation fluid control unit, arranged for connecting with an inlet / outlet port of said outer chamber and comprising a pump for circulating said temperature regulation fluid from said outer chamber and through a heat exchanger system located outside said inner chamber.

This invention discloses a deep standard penetration test apparatus, comprising an umbilical cable, a sheath, an air hammer, and a penetrator. The sheath is open at the top and closed at the bottom, and has at least one vent hole with a one-way valve installed inside. A positioning rod is located inside the sheath, and the air hammer is installed inside the sheath and sleeved on the positioning rod, moving up and down along the positioning rod. The umbilical cable is hollow, with one end sleeved on the positioning rod and connected to the air hammer's air passage, and the other end extending out of the top of the sheath and connected to an external air supply device and data acquisition instrument. The bottom of the sheath is connected to the penetrator, and a pressure sensor and a counter are located between the penetrator and the sheath. A depth sensor is located outside the penetrator. This invention also discloses a deep standard penetration test method. This invention can effectively eliminate energy loss of the probe, improve the test efficiency of the standard penetration test, increase the applicable test depth, and provide accurate measurement results.

The invention relates to the technical field of biomedicine, in particular to an umbilical cord mesenchymal stem cell exosome and a preparation method and application thereof.The umbilical cord mesenchymal stem cell exosome is derived from umbilical cord mesenchymal stem cells expressing S100g-MTOR binding domain fusion protein and can inhibit excessive autophagy through an S100g / MTOR signal channel, and therefore intestinal mucosal barrier damage caused by antibiotics is relieved. The preparation method comprises the following steps: constructing an expression vector, transfecting and screening a stable expression cell strain, performing serum-free culture, collecting a culture supernatant, purifying the exosome and the like. The exosome disclosed by the invention can be used for preparing a medicine for treating antibiotic-related intestinal mucosal barrier injury, has the advantages of strong targeting property, definite action mechanism, remarkable curative effect and the like, and provides a new choice for preventing and treating antibiotic-related intestinal adverse reactions.

The invention belongs to the technical field of medicines, and particularly relates to a composition containing mesenchymal stem cells and application of the composition in preparation of products for resisting premature ovarian failure. The invention relates to a composition containing mesenchymal stem cells. The umbilical cord mesenchymal stem cell gel is prepared from the following components in percentage by weight: 10 percent of umbilical cord mesenchymal stem cells, 4 to 6 percent of human serum albumin stock solution, 1 to 2 percent of ginkgo biloba extract, 1 to 3 percent of coix seed oil, 2 to 2.5 percent of flavonol glycoside, 1.1 to 1.3 percent of vitamin E, 0.4 to 0.8 percent of glutathione, 0.5 to 1.5 percent of sodium hyaluronate, 0.5 to 1.0 percent of phycocyanin, 1.2 to 1.8 percent of zinc gluconate, 0.5 to 0.8 percent of heparin calcium, 0.1 to 0.3 percent of pH regulator and the balance of normal saline. The composition disclosed by the invention can be used for preparing products for resisting premature ovarian failure and has a very good effect.

The invention relates to the technical field of biological medicines, in particular to a mesenchymal stem cell preparation for treating diabetes and a preparation method thereof. The stem cell preparation is prepared from the following components: umbilical cord mesenchymal stem cells and naringin coated SiO2, and preparation raw materials of the naringin coated SiO2 are prepared from the following components in parts by weight: 10 to 15 parts of tetraethoxysilane (TEOS), 4 to 6 parts of 3-mercaptopropyl oxysilane (MPTMS), 2 to 3 parts of naringin, 0.8 to 1.2 parts of succinic anhydride and 2 to 3 parts of cysteamine hydrochloride. The prepared stem cell preparation has synergistic blood lineage of each component, and can repair pancreas islet injury and inhibit inflammatory response.

The present invention relates to a repair composition, a facial mask essence and a preparation method therefor. The repair composition comprises the following components in percentage by weight: 10.0%-30.0% of an animal umbilical cord extract, 20.0%-50.0% of β-1.3 glucan and 20.0%-70.0% of a Portulacae herba extract. The repair composition of the present invention is used in cosmetics, and has the effects of significantly reducing wrinkle formation and delaying skin aging, thereby further achieving the effect of maintaining beauty and youth. The repair composition does not cause users to have an allergic reaction and is safe to use.

The invention relates to the technical field of rhinitis spray preparation, in particular to a method for preparing allergic rhinitis spray from umbilical cord mesenchymal stem cell exosomes, which comprises the following steps: 1, umbilical cord treatment; 2, culturing umbilical cord mesenchymal stem cells; 3, preparing an umbilical cord mesenchymal stem cell exosome; and 4, preparing the rhinitis spray. The rhinitis spray prepared by the method disclosed by the invention is simpler and more convenient to use. The exosome, the platelet growth factor and other substances in the rhinitis spray well solve the core problems of single curative effect, large side effect, low compliance and the like in the traditional rhinitis treatment, and through the induction and repair functions of the stem cell exosome and the bactericidal ability of the antibacterial peptide, the nasal cavity environment is improved, the anaphylactic reaction is reduced, the nasal mucosa is repaired, and the rhinitis treatment effect is improved. The allergic rhinitis is expected to be fundamentally treated.

The invention belongs to the technical field of biology, and discloses a fusion type polypeptide for improving the activity of umbilical cord mesenchymal stem cells and application of the fusion type polypeptide. The amino acid sequence of the fusion type polypeptide provided by the invention is any one sequence as shown in SEQ ID NO.1-3. The fusion type polypeptide is obtained by integrating an extracellular matrix amino acid sequence and a heparin amino acid sequence. The umbilical cord mesenchymal stem cells obtained by culturing the fusion type polypeptide have good multiplication capacity, can promote expression of the Ki67 gene and inhibit aging of the umbilical cord mesenchymal stem cells, and have wide application prospects.

The invention provides an osteogenic induced differentiation kit, a culture medium and a preparation method of the culture medium, and particularly relates to the technical field of stem cells. The kit comprises a DMEM (dulbecco's modified eagle medium) basal culture medium, fetal calf serum, dexamethasone, vitamin C, beta-glycerol phosphate, mesenchymal stem cell osteogenesis induced supernatant, alizarin red S staining solution and acetic acid. According to the kit provided by the invention, the problems of slow calcium nodule formation, small calcium nodule quantity and small calcium nodule in the osteogenic induced differentiation of the umbilical cord mesenchymal stem cells in the prior art are solved, so that the calcium nodule formation of the umbilical cord mesenchymal stem cells is effectively promoted, meanwhile, the calcium nodule quantity can be increased, and the osteogenic induced differentiation period is shortened.

The invention provides an extraction method of umbilical cord mesenchymal stem cell exosomes. The extraction method comprises the following steps: S1, collecting umbilical cord mesenchymal stem cell culture supernatant; s2, centrifuging the culture supernatant under a centrifugal force of 250-350 g, and collecting the supernatant to obtain a first mixed solution; s3, centrifuging the first mixed solution under a centrifugal force of 1500-2500 g, and collecting a supernatant to obtain a second mixed solution; s4, centrifuging the second mixed solution under a centrifugal force of 9000-11000 g, and collecting a supernatant to obtain a third mixed solution; and S5, filtering the third mixed solution, centrifuging under the centrifugal force of 90000-110000 g, collecting the precipitate, adding a PBS buffer solution, centrifuging under the centrifugal force of 90000-110000 g, and collecting the precipitate to obtain the umbilical cord mesenchymal stem cell exosome. The umbilical cord mesenchymal stem cell exosome with the purity up to 99% is extracted from the culture supernatant through twice low-speed centrifugation and three times of high-speed centrifugation.